BioBlast w/e 08 Dec 23
The FDA approved Vertex/CRISPR Therapeutics’ Casgevy® and Bluebird Bio’s Lyfgenia®, the first cell-based gene therapies to treat sickle cell disease…
Source: lexology.com
Roche Susvimo News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Roche Susvimo. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Roche Susvimo Today - Breaking & Trending Today
Outlook on the Age-related Macular Degeneration Global Market to 2030 - Players Include Bayer, Pfizer, Bausch Health and Amgen Among Others
/PRNewswire/ -- The "Age-related Macular Degeneration Market Size, Share & Trends Analysis Report by Product (Eylea, Lucentis, Beovu), by Disease Type (Wet...
Source: prnewswire.com
Global Age-related Macular Degeneration Market Report 2022
Dublin, Dec. 02, 2022 (GLOBE NEWSWIRE) -- The "Age-related Macular Degeneration Market Size, Share & Trends Analysis Report by Product (Eylea,...
Source: globenewswire.com
Investegate |F. Hoffmann-La Roche Ltd Announcements | F. Hoffmann-La Roche Ltd: FDA approves Roche's Susvimo, a first-of-its-kind therapeutic approach for neovascular or "wet" age-related macular degeneration (nAMD)
Investegate announcements from F. Hoffmann-La Roche Ltd, FDA approves Roche’s Susvimo, a first-of-its-kind therapeutic approach for neovascular or “wet” age-related macular degeneration (nAMD)
Source: investegate.co.uk